Absence of Germline BRCA1 c. 68_69delAG and c. 5266dupC Mutations among Hormone Receptor-negative Breast Cancer Patients: A First Impression at a Tertiary Cancer-care Facility in Tanzania

Simple item page
dc.contributor.authorRweyemamu, Linus Paul
dc.contributor.authorAkan, Gokce
dc.contributor.authorMbotwa, Christopher H
dc.contributor.authorDharsee, Nazma
dc.contributor.authorNamkinga, Lucy
dc.contributor.authorLyantagaye, Sylvester L
dc.contributor.authorMselle, Ted F
dc.contributor.authorAtalar, Fatmahan
dc.date.accessioned2022-11-24T13:17:38Z
dc.date.available2022-11-24T13:17:38Z
dc.date.issued2021-12-29
dc.descriptionNILen_US
dc.description.abstractThe germline BRCA1 c.68_69delAG (185delAG) and c.5266dupC (5382insC) mutations are associated with hormone receptor-negative breast cancer (BC). Limited studies have examined their contribution to alarming BC incidence in Sub Saharan Africa (SSA). Our study aimed to examine the contribution of germline BRCA1 c.68_69delAG and c.5266dupC mutations to BC incidence among hormone receptor-negative BC patients admitted to Ocean Road Cancer Institute in Tanzania. Face-to-face interviews were conducted to capture socio-demographic characteristics, anthropometric measurements, family history of cancer and reproductive information from each patient. Their histopathological data were extracted from the hospital medical records. The germline BRCA1 founder mutations were analyzed on blood samples using Sanger sequencing technology. The patients mean age at diagnosis was 47.05 ± 12.82 years. A family history of cancer was observed in 13.6% of patients. The germline BRCA1 c.68_69delAG and c.5266dupC mutations were not detected in the study group. Our findings indicate that the germline BRCA1 c.68_69delAG and c.5266dupC mutations do not contribute to BC manifestation in hormone receptor-negative BC patients in Tanzania. Thus, screening BC patients for these mutations has no clinical relevance. Our data further suggest that the c.68_69delAG and the c.5266dupC mutations should not be considered when developing genetic testing guidelines in Tanzania.en_US
dc.description.sponsorshipMinistry of Education, Science and Technology; University of Dar es Salaam, grant no. MCHAS-20131en_US
dc.identifier.citationRweyemamu LP, Akan G, Mbotwa CH, Dharsee N, Namkinga LA, Lyantagaye SL, Mselle TF and Fatmahan Atalar. Absence of Germline BRCA1 c. 68_69delAG and c. 5266dupC Mutations among Hormone Receptor-negative Breast Cancer Patients: A First Impression at a Tertiary Cancer-care Facility in Tanzania. Tanzania Journal of Science 2021;47(5):1859-69. DOI: https://dx.doi.org/10.4314/tjs.v47i5.27en_US
dc.identifier.doihttps://dx.doi.org/10.4314/tjs.v47i5.27
dc.identifier.urihttp://hdl.handle.net/20.500.11810/5911
dc.language.isoen_USen_US
dc.publisherAJOLen_US
dc.relation.ispartofseries47;5
dc.subjectBreast cancer, germline BRCA1 mutation, c.68_69delAG (185delAG), c.5266dupC (5382insC), Tanzaniaen_US
dc.titleAbsence of Germline BRCA1 c. 68_69delAG and c. 5266dupC Mutations among Hormone Receptor-negative Breast Cancer Patients: A First Impression at a Tertiary Cancer-care Facility in Tanzaniaen_US
dc.typeJournal Article, Peer Revieweden_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Paper 2.pdf
Size:
611.02 KB
Format:
Adobe Portable Document Format
Description:
Published article 2
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Department of Microbiology/Immunology